Home > Press > Launch of Bio Nano Consulting Ushers in New Era in Bio-Nanotech
Abstract:
New specialist product development consultancy will enable companies to realise the biomedical and pharmaceutical applications of nanotechnology
A significant step forward in the practical delivery of nanotech for biomedical applications was taken last night with the official launch of Bio Nano Consulting. Formerly known as the Bio Nano Centre, the new Bio Nano Consulting (BNC) is a specialist product development consultancy applying nanotechnology tools to address real-world problems from the biomedical industry. Established in late 2007, BNC provides a seamless concept-to-market route for the bio-nanotechnology sector, and already has two projects underway with major pharmaceutical and diagnostics companies.
Announcing the launch, Professor John Wood, Principal, Faculty of Engineering and Chair in Material Science at Imperial College, London summarised BNC as providing companies with "access to brains and facilities". BNC combines world leading experts in nanotechnology and biomedical engineering, experienced product development professionals and a £5m investment in infrastructure, instrumentation and working capital, to provide companies with an unparalleled resource. Particular specialist areas include virtual design, rapid prototyping and nano-characterisation.
Bio Nano Consulting CEO, Dr David Sarphie - a biotechnology professional with a wealth of senior management experience - commented "Over the next 20 years or so, the developing science of nanotechnology is going to transform healthcare - and generate globally significant revenues. For example, it is estimated that by 2015, some 50-60% of drugs will have involved nanotechnology in some stage of the development or delivery process. BNC offers a new way for companies to develop exciting new therapies, diagnostics and biomedical products that make use of nanotechnology."
Expertise comes from senior researchers at Imperial College London, the University College London's London Centre for Nanotechnology (LCN) and the UK's National Physical Laboratory. An experienced board including Professors Gabriel Aeppli and Mike Horton of LCN and Professor Tony Cass of Imperial College will provide particular expertise. In addition, the BNC's Industrial Advisory Board, composed of representatives from companies working in the biomedical sector, will ensure that technological concepts are successfully turned into reality, and projects will be run to schedule by highly experienced product development managers.
####
About Bio Nano Consulting
The BNC is a specialist research and development consultancy operating in the convergent field of bionanotechnology. A joint venture of Imperial College London and University College London, the BNC is funded through the Technology Strategy Board (TSB) with additional support from the London Development Agency (LDA).
Along with its partner organisation, the National Physical Laboratory, the BNC offers a service to the biomedical and healthcare industries in microsystems and nanotechnology. This encompasses design, 3-D modelling and visualisation, rapid prototyping, and characterisation.
For more information, please click here
Contacts:
Product
Enquiries
Bio Nano Consulting
Dr David Sarphie CEO
t: +44 (0)207 268 3032
Media enquiries
Alto Marketing Limited
Neil Ravenhill
t: +44 (0)1489 557672
Copyright © Bio Nano Consulting
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||